

第40回札幌国際がんシンポジウム

The 40th Sapporo International Cancer Symposium

Tumor heterogeneity:
From genomic evolution to clinical impact

会期 2022年
6月23日~25日

June 23 (Thu) - 25 (Sat), 2022

Hybrid Meeting (On-site/Online)

会場 **ロイトン札幌**

Royton Sapporo, Sapporo, Hokkaido Japan

主催 **公益財団法人札幌がんセミナー**
Sapporo Cancer Seminar Foundation

世話人 **村上 善則** 東京大学医科学研究所
Yoshinori Murakami (The University of Tokyo)

落合 淳志 東京理科大学・国立がん研究センター
Atsushi Ochiai (Tokyo University of Science/National Cancer Center)

柴田 龍弘 東京大学医科学研究所・国立がん研究センター
Tatsuhiro Shibata (The University of Tokyo/National Cancer Center)

舩森 直哉 札幌医科大学医学部
Naoya Masumori (Sapporo Medical University)

Patrick TAN Duke-国立シンガポール大学医科大学
(Duke-NUS Medical School)

Program & Abstract

June 24 (Fri)

9:00-9:10	Welcome address Masanori Hatakeyama
9:10-10:00	Keynote Lecture 1 Chair: Yoshinori Murakami (The University of Tokyo)
K1	Comprehensive driver landscape of gastric cancer14 Tatsuhiko Shibata The Institute of Medical Science, The University of Tokyo, Japan
10:00-12:15	Session 1. Genomic evolution Chair: Atsushi Ochiai (Tokyo Science University / National Cancer Center)
S1-1	Clonal expansion in normal tissues18 Nobuyuki Kakiuchi Kyoto University
10:30-10:45	Break
S1-2	Genetic basis of mosaic chromosomal alteration highlights its cellular origin and biology20 Chikashi Terao Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences
S1-3	Cancer heterogeneity of infant leukemia and its implication for prognosis and treatment22 Junko Takita Department of Pediatrics, Graduate School of Medicine, Kyoto University
S1-4	Various heterogeneities about BRCA1 and BRCA224 Yukihide Momozawa RIKEN Center for Integrative Medical Sciences
12:15-12:30	Break
12:30-13:20	Luncheon Seminar 1 Chair: Wataru Obara (Iwate Medical University) Co-sponsored: MSD K.K.
LS-1	Intratumoral Heterogeneity in renal cell carcinoma and current treatment strategy ..82 Ryuichi Mizuno, Mototsugu Oya Department of Urology, Keio University, School of Medicine
13:20-13:30	Break

13:30-14:20 Keynote Lecture 2

Chair: Atsushi Ochiai (Tokyo Science University / National Cancer Center)

K2 Gastric Cancer beyond Gene Mutations : Single-cells and Epigenomes.....16

Patrick Tan^{1,2,3}

¹⁾ Duke-NUS Medical School

²⁾ Genome Institute of Singapore

³⁾ Cancer Science Institute of Singapore, NUS

14:20-14:30 Break

14:30-15:30 Poster Session 1

Chair: Tatsuhiro Shibata (The University of Tokyo, National Cancer Center)

P1-1 Heterogeneous impact of germline pathogenic variants on lymphoma risk56

Yoshiaki Usui¹, Yusuke Iwasaki¹, Keitaro Matsuo³, Mikiko Endo¹, Yoichiro Kamatani⁴, Makoto Hirata⁵, Kokichi Sugano⁵, Teruhiko Yoshida⁵, Koichi Matsuda⁴, Yoshinori Murakami⁴, Yoshinobu Maeda², Hidewaki Nakagawa¹, Yukihide Momozawa¹

¹⁾ RIKEN

²⁾ Okayama University

³⁾ Aichi Cancer Center

⁴⁾ The University of Tokyo

⁵⁾ National Cancer Center Hospital

P1-2 Primate-specific gene X is a novel prognostic factor in malignant pancreatic cancer.....57

Shoichiro Tange¹, Tomomi Hirano¹, Asae Okuyama¹, Masashi Idogawa¹, Eishu Hirata², Issei Imoto³, Takashi Tokino¹

¹⁾ Med. Genome Sci., Inst. Frontier Med., Sappor Med. Univ.

²⁾ Kanazawa Univ. Cancer Res. Inst. Div. Tumor Cell Biol.

³⁾ Aichi Cancer Ctr. Res. Inst.

P1-3 Molecular profiling of cancer-related gene alterations in Japanese patients with multiple myeloma58

Yasushi Sasaki^{1,2}, Hisayo Fukushima^{2,3}, Hiroshi Ikeda⁴, Kazuya Ishiguro⁵, Asami Matsuda¹, Shoichiro Tange², Masashi Idogawa², Akihiro Sakurai³, Takashi Tokino²

¹⁾ Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo Medical University

²⁾ Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University

³⁾ Department of Medical Genetics, Sapporo Medical University

⁴⁾ Department of Hematology, Sapporo Medical University

⁵⁾ Department of Gastroenterology, Sapporo Medical University

P1-4 Association of mosaic chromosomal alterations with the development of various types of cancer and body mass index59

Keiko Hikino, Chikashi Terao

RIKEN Center for Integrative Medical Sciences

P1-5 Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer ...60

Atsushi Takano^{1,2,3}, Yoshihiro Yoshitake⁴, Masanori Shinohara⁴, Yataro Daigo^{1,2,3}

¹⁾ Center for Antibody and Vaccine Therapy, Institute of Medical Science, The University of Tokyo

²⁾ Department of Medical Oncology and Cancer Center, Shiga University of Medical Science

³⁾ Center for Advanced Medicine against Cancer, Shiga University of Medical Science

⁴⁾ Department of Oral and Maxillofacial Surgery, Kumamoto University

P1-6 Substrate charge regulates stemness of cancer and pluripotent stem cells via metabolic control of pluripotency factors61

Masamichi Imajo¹, Akira Hirota¹, Ryosuke Miyazaki², Jian-Ping Gong³, Shinya Tanaka^{1,2}

¹⁾ Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University

²⁾ Department of Cancer Pathology, Faculty of Medicine, Hokkaido University

³⁾ Laboratory of Soft & Wet Matter, Faculty of Advanced Life Science, Hokkaido University

P1-7	Therapeutic potential of cancer vaccine based on MHC class I cryptic peptides derived from non-coding regions	62
	Serina Tokita, Takayuki Kanaseki, Toshihiko Torigoe Department of Pathology, Sapporo Medical University	
P1-8	Identification and functional analysis of HLA class II neoantigens in HLA class II negative colorectal cancer tissues	63
	Satoru Matsumoto ^{1,2} , Takayuki Kanaseki ¹ , Serina Tokita ¹ , Toshihiko Torigoe ¹ ¹ Department of Pathology, Sapporo Medical University School of Medicine ² IMS Sapporo Digestive Disease Center General Hospital	
P1-9	A lncRNA associated with chronic gastritis and gastric cancer inhibits apoptosis through stress granule formation	64
	Hiroshi Kitajima ¹ , Reo Maruyama ² , Akira Takasawa ³ , Takeshi Niinuma ¹ , Eiichiro Yamamoto ¹ , Kazuya Ishiguro ¹ , Ayano Yoshido ¹ , Masahiro Kai ¹ , Makoto Osanai ³ , Takashi Tokino ⁴ , Hiroshi Nakase ⁵ , Hiromu Suzuki ¹ ¹ Dept. of Molecular Biology, Sapporo Medical Univ. ² Project for Cancer Epigenome, The Cancer Institute of JFCR ³ Dept. of Pathology, Sapporo Medical Univ. ⁴ Dept. of Medical Genome Sciences, Research Institute of Frontier Medicine, Sapporo Medical Univ. ⁵ Dept. of Gastroenterology and Hepatology, Sapporo Medical Univ.	
P1-10	<i>Helicobacter pylori</i> CagA causes transient BCRAness to induce genome instability in gastric epithelial cells	65
	Naoko Kamiya ¹ , Masanori Hatakeyama ² ¹ Hokkaido University ² Institute of Microbial Chemistry	
P1-11	Intratumoral heterogeneity in colorectal cancer -Increasing malignancy of cancer cells by Mφs in tumor budding area-	66
	Rintaro Ohe, Takanobu Kabasawa, Mitsuru Futakuchi Department of Pathology, Yamagata University Faculty of Medicine	

15:30-15:40 Break

15:40-18:10 Session 2. Tumor heterogeneity

Chair: Yoshinori Murakami (The University of Tokyo)

S2-1	Epigenetic remodelling of tumor microenvironment to overcome immunotherapy resistance	26
	Alfred Cheng School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong	
S2-2	The landscape of HLA-presenting antigenic peptides and their immunogenic heterogeneity	28
	Toshihiko Torigoe, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Terufumi Kubo, Kenji Murata, Tomoyuki Minowa, Hisashi Uhara, Masahiro Matsuki, Naoya Masumori Sapporo Medical University	
S2-3	Gastrointestinal cancer evolution and its implications for therapeutics and biomarker development	30
	Marco Gerlinger Barts Cancer Institute, Queen Mary University of London, UK	

S2-4	Applications of Spatial Transcriptome Analysis to elucidate the cancer heterogeneity	32
	Yutaka Suzuki	
	The University of Tokyo	
S2-5	Cancer heterogeneity from the perspective of stromal fibroblasts	34
	Atsushi Ochiai ^{1,2}	
	¹⁾ Research Institute for Biomedical Sciences, Tokyo University of Science	
	²⁾ National Cancer Center	

June 25 (Sat)

9:00-10:00		Session 3. Tumor heterogeneity and plasticity
		Chair: Yoshinori Murakami (The University of Tokyo)
S3-1	MYC drives small cell lung cancer (SCLC) subtype plasticity	36
	Trudy G. Oliver	
	Duke University, Durham, NC, USA	
S3-2	The impact of vascular endothelial cell heterogeneity in tumor microenvironment. ...	38
	Kyoko Hida	
	Vascular Biology and Molecular Biology, Graduate school of Dental Medicine, Hokkaido University	
10:00-12:15		Session 4. Technological advances
		Chair: Yutaka Suzuki (The University of Tokyo)
S4-1	Cell-type specific post-transcriptional regulation is pervasive	40
	Julia Salzman	
	Department of Biomedical Data Science and of Biochemistry, Stanford University	
	10:30-10:45	Break
S4-2	Dynamics and colocalization of deep learning-based cell states behind single cell and spatial transcriptome observation.....	42
	Yasuhiro Kojima, Teppei Shimamura	
	Nagoya University	
S4-3	Pan-cancer pervasive upregulation of 3' UTR splicing drives tumourigenesis.....	44
	Yvonne Tay ^{1,2} , Jia Jia Chan ² , Bin Zhang ²	
	¹⁾ National University of Singapore	
	²⁾ Cancer Science Institute of Singapore	
S4-4	Immunosuppression by regulatory T cells in the tumor microenvironment	46
	Hiroyoshi Nishikawa ^{1,2}	
	¹⁾ Division of Cancer Immunology, Research Institute/ EPOC, National Cancer Center	
	²⁾ Department of Immunology, Nagoya University Graduate School of Medicine	
	12:15-12:30	Break
12:30-13:20		Luncheon Seminar 2
		Chair: Atsushi Mizokami (Kanazawa University Graduate School of Medical Science)
		Co-sponsored: Janssen Pharmaceutical K.K.
LS-2	Spatial and temporal heterogeneity of prostate cancer, basics to clinical implications	84
	Shusuke Akamatsu	
	Department of Urology, Kyoto University Graduate School of Medicine	
	13:20-13:30	Break

- P2-1 Differences of the molecular mechanisms in dedifferentiation potential of breast cancer cells using hydrogels.....68**
 Jun Suzuka¹, Sumito Saeki^{2,3}, Kohei Kumegawa¹, Yoko Takahashi^{1,3}, Takayuki Ueno^{1,3}, Shinji Ohno^{1,3}, Masumi Tsuda^{4,5}, Shinya Tanaka^{4,5}, Reo Maruyama^{1,2}
¹NEXT-Ganken Prog., JFCR
²Project Cancer Epigenome, The Cancer Inst., JFCR
³Breast Surg. Oncol., Cancer Inst. Hosp., JFCR
⁴Dept. of Cancer Pathol., Fac. of Med., Hokkaido Univ.
⁵Inst. for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido Univ.
- P2-2 Analysis of novel long non-coding RNA in head and neck cancer.69**
 Takeshi Niinuma, Hiroshi Kitajima, Kai Masahiro, Hiromu Suzuki
 Sapporo Medical University of Medicine
- P2-3 GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer70**
 Reo Maruyama^{1,2}, Kohei Kumegawa², Yoko Takahashi^{2,3}, Sumito Saeki¹, Liying Yang¹, Shinji Ono^{2,3}, Takayuki Ueno^{2,3}
¹Project for Cancer Epigenomics, Cancer Institute, JFCR
²NEXT-Ganken Program, JFCR
³Breast Oncology Center, Cancer Institute Hospital, JFCR
- P2-4 Reduced stromal expression of CXCL12 is associated with the aggressiveness of tongue oral squamous cell carcinoma.....71**
 Akira Yorozu^{1,2}, Shohei Sekiguchi^{2,3}, Akira Takasawa⁴, Takeshi Niinuma², Makoto Kurose¹, Kazufumi Obata¹, Akito Kakiuchi¹, Makoto Osanai⁴, Akihiro Miyazaki³, Kenichi Takano¹, Hiromu Suzuki²
¹Dept. Otolaryngology-head and Neck Surgery., Sapporo Med. Univ. Sch. Med.
²Dept. Mol. Biol., Sapporo Med. Univ. Sch. Med.
³Dept. Oral Surg., Sapporo Med. Univ. Sch. Med.
⁴Dept. Path., Sapporo Med. Univ. Sch. Med.
- P2-5 Analysis of characteristics of synovial sarcoma stem cells induced by synthetic polymer hydrogels.....72**
 Yuki Terashima¹, Masumi Tsuda^{2,3}, Kyosuke Fujishima¹, Kosei Nakamura¹, Lei Wang^{2,3}, Jian Ping Gong^{3,4}, Shinya Tanaka^{2,3}
¹Sch. of Med. 6th Grade, Hokkaido Univ., Sapporo, Japan
²Dep. of Cancer Pathol., Faculty of Med., Hokkaido Univ., Sapporo, Japan
³WPI-ICReDD, Hokkaido Univ., Sapporo, Japan
⁴Lab. of Soft and Wet Matter, Faculty of Adv. Life Science, Hokkaido Univ., Sapporo, Japan
- P2-6 Molecular characterization of HJURP as a new cancer biomarker and therapeutic target for oral cancer.....73**
 Bayarbat Tsevegjav^{1,2}, Atsushi Takano^{1,2,3}, Ming Zhu^{1,2}, Yoshihiro Yoshitake⁴, Masanori Shinohara⁴, Yataro Daigo^{1,2,3}
¹Department of Medical Oncology and Cancer Center, Shiga University of Medical Science
²Center for Advanced Medicine against Cancer, Shiga University of Medical Science
³Center for Antibody and Vaccine Therapy, Institute of Medical Science, The University of Tokyo
⁴Department of Oral and Maxillofacial Surgery, Kumamoto University
- P2-7 Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed neoantigen in clear cell renal cell carcinoma.....74**
 Masahiro Matsuki^{1,2,5}, Yoshihiko Hirohashi², Munehide Nakatsugawa^{2,3}, Aiko Murai², Terufumi Kubo², Takayuki Kanaseki², Tomohide Tsukahara², Shinichi Hashimoto⁴, Naoya Masumori⁵, Toshihiko Torigoe²
¹Hakodate Goryokaku Hospital
²Department of Pathology, Sapporo Medical University School of Medicine
³Department of Diagnostic Pathology, Tokyo Medical University Hachioji Medical Center
⁴Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University
⁵Department of Urology, Sapporo Medical University School of Medicine

- P2-8 Identification of new targets for pancreatic cancer stem cells using hydrogel and development of therapeutic methods.....75**
 Lei Wang⁸⁸^{1,2}, Yuma Aoki³, Masumi Tsuda^{1,2}, Shinya Tanaka^{1,2}
¹Institute for Chemical Reaction Design and Discovery Hokkaido University
²Department of Cancer Pathology, Faculty of Medicine, Hokkaido University
³Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido
- P2-9 Stromal AEBP1 promotes development of head and neck squamous cell carcinoma..76**
 Shohei Sekiguchi¹, Akira Yorozu^{2,3}, Fumika Okazaki^{1,2}, Eiichiro Yamamoto^{2,4}, Takeshi Niinuma², Akira Takasawa⁵, Gota Sudo⁴, Yui Hatanaka^{1,2}, Ayano Yoshido², Hiroshi Kitajima², Masahiro Kai², Makoto Osanai⁵, Yoshihiko Hirohashi⁶, Takashi Kojima⁷, Akihiro Miyazaki¹, Hiromu Suzuki²
¹Department of Oral Surgery., Sapporo Medical University School of Medicine
²Department of Molecular Biology., Sapporo Medical University School of Medicine
³Dept. Otolaryngol., Sapporo Med. Univ. Sch. Med.
⁴Dept. Gastroenterol Hepatol., Sapporo Med. Univ. Sch. Med.
⁵2nd Dept. Path., Sapporo Med. Univ. Sch. Med.
⁶1st Dept. Path., Sapporo Med. Univ. Sch. Med.
⁷Dept. Cell Sci., Inst. Frontier Med., Sapporo Med. Univ. Sch. Med.
- P2-10 Genetic analysis of postmortem tissue samples for patient with castration-resistant prostate cancer: A case study.....77**
 Ko Okabe, Kohei Hashimoto, Hidetoshi Tabata, Tetsuya Shindo, Toshiaki Tanaka, Naoya Masumori
 Department of Urology, Sapporo Medical University School of Medicine
- P2-11 Comprehensive association analysis between clustered microRNA and cancer: a machine learning study with large-scale data78**
 Masanori Nojima, Yin Mo
 The Institute of Medical Science, The University of Tokyo
- P2-12 Novel drug formulation for potentiation of therapeutic response using the lymphatic drug delivery system.....79**
 Radhika Mishra, Ariunbuyan Sukhbaatar, Maya Sakamoto, Shiro Mori, Tetsuya Kodama
 Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University
- P2-13 Targeting lymph node metastasis through lymphatic drug delivery system by administration of docetaxel80**
 Ariunbuyan Sukhbaatar^{1,2}, Shiro Mori^{1,2}, Tetsuya Kodama^{1,2}
¹Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University
²Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University
- P2-14 Identification of URST7 as a prognostic biomarker and therapeutic target for breast cancer81**
 Regina Mbugua^{1,2}, Takano Atsushi^{1,2,3}, Tsevegjav Bayarbat^{1,2}, Mihagi Yohei⁴, Daigo Yataro^{1,2,3}
¹Dep. Med. Oncol. & Cancer Ctr., Shiga Univ. Med. Sci. Otsu, Shiga, Japan
²Ctr. Advanced Med. against Cancer, Shiga Univ. of Med. Sci., Otsu, Shiga, Japan
³Ctr. Antibody and Vaccine Ther. Inst. Med. Sci., Univ. Tokyo, Tokyo, Japan
⁴Mol. Pathol. & Genet. Div., Kanagawa Cancer Ctr., Kanagawa, Japan

15:00-17:00 Session 5. Clinical impact and drug resistance

Chair: Naoya Masumori (Sapporo Medical University)

- S5-1** Microsatellite instability-high CRC acquires frequent sub-clonal immune escape mechanisms by Darwinian evolution.48
Koshi Mimori
Kyushu University Beppu Hospital
- S5-2** Novel treatment approach for targeting RAS Q61 mutant cancers50
Yoshihisa Kobayashi
National Cancer Center Research Institute
- S5-3** Current treatment strategy for muscle invasive and metastatic bladder cancer52
Naoya Masumori
Sapporo Medical University
- S5-4** Cell context-dependent roles of a cell adhesion molecule, CADM1, in human oncogenesis.54
Yoshinori Murakami
Division of Molecular Pathology, The Institute of Medical Science, The University of Tokyo

17:00-17:10 Closing remark

Yoshinori Murakami